Seeking Alpha

FDA denies Amarin's ANCHOR SPA appeal

  • The FDA has not accepted Amarin's (AMRN) appeal regarding the rescission of the SPA for Vascepa's ANCHOR study.
  • The company also says its "request for a meeting at a high level within the FDA regarding the appeal was not granted."
  • AMRN says it plans to continue to pursue the appeal. (8-K)
  • AMRN -12% premarket
From other sites
Comments (6)
  • mangum
    , contributor
    Comments (65) | Send Message
    FDA, bought and paid for, just like every other corner of the Obama Carnival.
    22 Nov 2013, 07:46 AM Reply Like
  • SimonSaysShort
    , contributor
    Comments (109) | Send Message
    Nice! Blame Obama this time...that is a new angle for AMRN longs...
    22 Nov 2013, 08:02 AM Reply Like
  • Quoth the Raven
    , contributor
    Comments (2076) | Send Message
    Saw that one coming, a MILE away :
    22 Nov 2013, 08:01 AM Reply Like
  • voltnfan
    , contributor
    Comments (7) | Send Message
    No other company generates more bad news than Amarin. It never ends! But Joe Z continues to give himself pay increases! Amazing!
    22 Nov 2013, 08:17 AM Reply Like
  • tonyeg
    , contributor
    Comments (166) | Send Message
    I became concerned when JZ only bought +50k shares at $1.86...not a lot of conviction.
    22 Nov 2013, 08:17 PM Reply Like
  • suren037
    , contributor
    Comments (8) | Send Message
    the decision on 20th Dec is already out it seems: Screw AMRN .
    24 Nov 2013, 04:40 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector